By continuing to use the site you agree to our Privacy & Cookies policy

Your browser seems to have cookies disabled. For the best experience of this website, please enable cookies in your browser.


Your browser is no longer supported

For the best possible experience using our website we recommend you upgrade to a newer version or another browser.


SMC backs drug for male urinary symptoms in Scotland

The Scottish Medicines Consortium has approved solifenacin 6mg/tamsulosin 0.4mg (Vesomni) for use in NHS Scotland.

It has been accepted for the treatment of moderate to severe storage symptoms and voiding symptoms associated with benign prostatic hyperplasia (BPH) in men not adequately responding to monotherapy.

Tamsulosin is an alpha-blocker, commonly prescribed to treat lower urinary tract symptoms associated with BPH due to its efficacy in relieving symptoms related to urinary voiding.

Solifenacin is an anti-muscarinic treatment used to treat urge incontinence and increased urinary frequency and urgency.


Have your say

You must sign in to make a comment.

Related Jobs

Sign in to see the latest jobs relevant to you!